These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7577090)

  • 41. Adjuvant therapy for early breast cancer.
    Costa SD; Bischoff J
    N Engl J Med; 2007 Mar; 356(12):1268-9. PubMed ID: 17377168
    [No Abstract]   [Full Text] [Related]  

  • 42. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 43. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
    Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
    Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study.
    Conte PF; Rubagotti A; Falcone A; Gardin G; Nicolin A; Pronzato P; Rosso R; Amadori D; Gentilini P; Sismondi P
    Chemioterapia; 1987 Jun; 6(2 Suppl):712-3. PubMed ID: 3334664
    [No Abstract]   [Full Text] [Related]  

  • 46. Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma.
    Chen GY; Lee JY; Chen WC
    Br J Dermatol; 2005 Jun; 152(6):1383-5. PubMed ID: 15949026
    [No Abstract]   [Full Text] [Related]  

  • 47. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
    Trudeau ME
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):7-13. PubMed ID: 11396366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
    Fumoleau P; Devaux Y; Vo Van ML; Kerbrat P; Fargeot P; Schraub S; Mihura J; Namer M; Mercier M
    Drugs; 1993; 45 Suppl 2():38-45. PubMed ID: 7693420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
    Meinardi MT; Van Der Graaf WT; Gietema JA; Van Den Berg MP; Sleijfer DT; De Vries EG; Haaksma J; Boomsma F; Van Veldhuisen DJ
    Heart; 2002 Jul; 88(1):81-2. PubMed ID: 12067953
    [No Abstract]   [Full Text] [Related]  

  • 51. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Asola R; Kokko R; Ahlgren J; Auvinen P; Hemminki A; Paija O; Helle L; Nuortio L; Villman K; Nilsson G; Lahtela SL; Lehtiö K; Pajunen M; Poikonen P; Nyandoto P; Kataja V; Bono P; Leinonen M; Lindman H;
    Lancet Oncol; 2009 Dec; 10(12):1145-51. PubMed ID: 19906561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is adjuvant chemotherapy useful in lobular breast cancer patients?
    Liem X; Baranzelli MC; Penel N; Giard S; Bonneterre J
    Ann Oncol; 2011 Nov; 22(11):2532-2533. PubMed ID: 21700733
    [No Abstract]   [Full Text] [Related]  

  • 54. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; Palmieri C; Coombes RC
    Oncol Rep; 2007 Jan; 17(1):253-9. PubMed ID: 17143506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
    Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
    Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
    Colozza M; Bisagni G; Mosconi AM; Gori S; Boni C; Sabbatini R; Frassoldati A; Passalacqua R; Bian AR; Rodinò C; Rondini E; Algeri R; Di Sarra S; De Angelis V; Cocconi G; Tonato M
    Eur J Cancer; 2002 Nov; 38(17):2279-88. PubMed ID: 12441265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study.
    Gardin G; Barone C; Nascimben O; Ianniello G; Sturba F; Contu A; Pronzato P; Rosso R
    Eur J Cancer; 1996 Jan; 32A(1):176-7. PubMed ID: 8695230
    [No Abstract]   [Full Text] [Related]  

  • 59. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
    Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
    Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil.
    Li JJ; Di GH; Tang LC; Yu KD; Hu Z; Liu GY; Lu JS; Wu J; Han QX; Shen ZZ; Shao ZM
    Breast J; 2011; 17(6):657-60. PubMed ID: 21933300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.